tiprankstipranks
Trending News
More News >
Sana Biotechnology (SANA)
NASDAQ:SANA
US Market
Advertisement

Sana Biotechnology (SANA) Drug Pipeline

Compare
767 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Sc262
Large B-Cell Lymphoma, Non Hodgkin's Lymphoma
Phase I
Recruiting
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
Feb 22, 2024
Sc291
Systemic Lupus Erythematosus, Lupus Erythematosus, Sle (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
Phase I
Recruiting
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
Feb 12, 2024
Sc291
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Phase I
Active Not Recruiting
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
Apr 28, 2023

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Sana Biotechnology (SANA) have in its pipeline
      SANA is currently developing the following drugs: Sc262, Sc291, Sc291. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis